Liraglutide: Evaluation of Clinical Benefit in a Portuguese Population with Diabetes Difficult to Control
DOI:
https://doi.org/10.24950/rspmi.836Keywords:
Blood Glucose, Body Weight/drug effects, Diabetes Mellitus, Type 2/drug therapy, Hypoglycemic Agents, Liraglutide, Portugal, Treatment OutcomeAbstract
Introduction: Liraglutide is a GLP-1 receptor agonist available
in Portugal since January 2014. The authors intend to evaluate
the clinical benefit of this new drug in a population of diabetic
patients of high complexity, followed in a hospital consultation.
Material and Methods: Descriptive study including patients
with type 2 diabetes followed in Diabetes outpatient clinic of a
tertiary hospital treated with liraglutide. Analyzed data included
weight, waist circumference, glycated hemoglobin, creatinine,
estimated glomerular filtration rate and albuminuria/creatinine
ratio. Results: We included 20 patients, age 62.5 years [54.75-
68], diabetes for 15 years [10-21.5] polymedicated with difficult
glycemic control and good renal function. There was improvement
in glycemic control after 3 months of treatment, but this
was not maintained over time in most patients (median decrease
of, in absolute value, 0.25% in glycated hemoglobin). There
was a decrease of 2.25 kg in 12 months. The patients showed
slight increase of creatinine and decreased glomerular filtration
rate after 12 months, with no statistical significance. The drug
proved to be safe and well tolerated.
Discussion: There is great variability in the response to this
new therapeutic tool both in terms of glycemic control and
weight, with some patients showing significant benefit, even
though not statistically significant globally.
Conclusion: Liraglutide is a well-tolerated drug and useful in
selected patients. In the overall population studied we did not
find significant clinical benefit, but a subgroup of patients obtained
improvement in glycemic and/or weight control.
Downloads
References
Diabetes: Factos e Números - O Ano de 2014. Relatório Anual do Observatório Nacional da Diabetes 11/2015. Lisboa: Sociedade Portuguesa de Diabetologia; 2015.
Holst J. The physiology of Glucagon-like Peptide 1. Physiol Rev. 2007;87:1409-39.
Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet. 2006;368:1696-705.
Meier J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728-42.
Vilsboll T. Liraglutide: A new treatment for type 2 diabetes. Drugs Today. 2009;45:101.
Relatório de avaliação do pedido de comparticipação de medicamento para uso humano liraglutido (M-COMP-021/3). Infarmed. [consultado Junho 2016] Disponível em: http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/AVALIACAO_ECONOMICA_E_COMPARTICIPACAO/MEDICAMENTOS_USO_AMBULATORIO/MEDICAMENTOS_COMPARTICIPADOS/PDF/liraglutido_Victoza_parecernet_20140417_0.pdf
Henry R, Buse J, Sesti G, Davies M, Jensen K, Brett J, et al. Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin a1c: a meta-analysis of the liraglutide development program. Endocr Pract. 2011;17:906-13.
Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon- like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ .2012;344:d7771.
Jendle J, Nauck M, Matthews D, Frid A, Hermansen K, Düring M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-
analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163-72.
Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.
Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes. 2013;4:190-201.
Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretinbased agents confer renoprotection in diabetes? Nat Rev Nephrol. 2014;10:88-103.
Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-78.
Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89:3055-61.
Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15:197-207.
Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, et al. GLP- 1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012;61:1422-34.
Dubois-Laforgue D, Boutboul D, Lévy D, Joly D, Timsit J. Severe acute renal failure in patients treated with glucagon-like peptide-1 receptor
agonists. Diabetes Res Clin Pract. 2014;103:e53-e5.
Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy. 2012;32:e7-e11.
Victoza® EU Summary of Product Characteristics. EMA. [consultado Junho 2016 Disponível em: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf
Duarte R, Nunes JS, Dores J, Rodrigues E, Raposo JF, Carvalho D, et al. Recomendações Nacionais da SPD para o Tratamento da Hiperglicemia na Diabetes Tipo 2 – Versão Resumida. Rev Port Diabetes. 2013;8: 4-29.
Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014;38:140-49.
Sethi BK, Viswanathan V, Kumar A, Chatterjee S, Chandalia HB. Liraglutide in Clinical Practice: Insights from LEAD Programme. J Assoc Phys
India. 2010;6.
Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Diabetes Metab Syndr. 2015;9:30-3.
Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, et al. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52- week, open-label, parallel-group trial. J Diabetes Investig. 2015;7:76-84.
Davies M, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. JAMA. 2015;314:687.
Toyoda M, Yokoyama H, Abe K, Nakamura S, Suzuki D. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106:451-7.
Zavattaro M, Caputo M, Samà M, Mele C, Chasseur L, Marzullo P, et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50:620-6.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Medicina Interna
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
